In a recent regulatory update, the China Securities Regulatory Commission (CSRC) has issued a list of companies required to submit supplementary materials for their overseas listing applications. Among the firms receiving these requests is Wuhe Boao, which has been asked to provide further justification for the pricing of shares issued to new shareholders over the past 12 months.
The CSRC's international department has made supplemental information requests to a total of eight enterprises. For Wuhe Boao, the regulator has specifically called for clarification on several key points, instructing the company's legal counsel to verify and provide definitive legal opinions. The requirements are as follows:
Key Regulatory Inquiries
First, the company must detail the specific fulfillment of regulatory procedures, such as overseas investment and foreign exchange management, concerning its overseas subsidiaries and provide a conclusive opinion on compliance.
Second, in light of its debt repayment capacity, the company needs to explain whether situations involving share pledges or personal loan guarantees by the controlling shareholder and their spouse could lead to significant ownership disputes or a change in the controlling shareholder following the completion of the proposed share issuance.
Third, the company is required to justify the reasonableness of the share prices for investors who became shareholders within the last 12 months, explain the reasons for any price discrepancies among these investors, and provide a clear conclusion on whether any improper benefit transfers occurred.
Fourth, the company must clarify the compliance of its already implemented equity incentive plans. This includes detailing the composition and roles of participants, confirming any relationships with other shareholders or company directors and senior management, and assessing price fairness, agreement terms, decision-making processes, and operational standards. A definitive opinion on the plan's legality and the absence of improper benefit transfers is required.
Fifth, the company needs to state whether shares held by shareholders intending to participate in the proposed "full circulation" scheme are subject to any pledges, freezes, or other encumbrances.
Company Background and Pipeline
Wuhe Boao submitted its application for a main board listing on the Hong Kong Stock Exchange on February 27, 2026, with Huatai International acting as its sole sponsor.
According to its prospectus, Wuhe Boao is a biopharmaceutical company founded in 2010. It has focused from its inception on innovation in natural medicines, specializing in the research, development, and commercialization of novel, high-technology-barrier drugs. The company has also engaged in drug delivery system research to overcome technical bottlenecks in in-vivo drug delivery.
As of February 18, 2026, the company's product pipeline comprises one commercialized product, Sang Bo En® for Type 2 diabetes; three core products, including WH007 for polycystic ovary syndrome, WH006 for obesity, and WH002 for neoadjuvant treatment of breast cancer; and five other drug candidates.
Comments